Core Viewpoint - The article discusses the dual nature of AI in the collagen protein industry, highlighting both opportunities and challenges for companies like Jinbo Biological, which is heavily investing in AI to enhance product development and maintain competitive advantage [15]. Group 1: Company Overview - Jinbo Biological is recognized as an "invisible champion" in China's recombinant collagen protein industry, with annual revenues exceeding 1 billion yuan and a market capitalization that once reached 50 billion yuan [3]. - The company has achieved over 100% net profit growth for four consecutive years, but recently reported a decline in net profit for the first time since 2015, indicating a significant shift in performance [6][12]. Group 2: Market Dynamics - The collagen protein market is experiencing a cooling period after years of rapid growth, with projections indicating that the global collagen raw material market could reach $3.815 billion by 2030, with recombinant type III collagen accounting for 41.6% of that market [4]. - Jinbo Biological's product development advantages are notable, having three products certified as Class III medical devices, including the innovative "Wei Yimei" injection [5][6]. Group 3: Financial Performance - Jinbo Biological's revenue for 2025 was reported at 1.595 billion yuan, a year-on-year increase of 10.57%, but net profit fell by 10.09%, marking a stark contrast to previous years of growth [6][12]. - The company is under pressure to find new blockbuster products, as its flagship product "Wei Yimei" has seen a slowdown in growth, necessitating a shift in focus towards new product development [9][10]. Group 4: AI Investment and R&D - Jinbo Biological plans to invest 1.15 billion yuan in AI-related platform construction, which is expected to enhance the efficiency of product development and reduce research and development cycles [2][13]. - The integration of AI has reportedly reduced the R&D cycle from 18 months to 12 months, indicating a 33% increase in efficiency [13]. Group 5: Competitive Landscape - The competitive landscape for recombinant collagen protein is intensifying, with at least 18 products having obtained Class III medical device certification, making it harder for any single product to dominate the market [16]. - The article notes that the marketing and consumer expectations have shifted, with visible results becoming increasingly important for product success [16][19]. Group 6: Future Directions - Jinbo Biological is exploring applications of recombinant human collagen beyond aesthetic medicine, including wound care and orthopedic implants, which could redefine the industry [14][22]. - The company aims to leverage the current market cooling period to focus on research and product refinement, potentially leading to innovations that extend beyond traditional cosmetic applications [22].